Inhibrx Biosciences
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Inhibrx Biosciences (INBX) | 1.02B | -7.61 | -11.86 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 58.4% below Morningstar's fair value estimate.
Fair value
Inhibrx Biosciences Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 24% discount to our quantitative fair value estimate of $109.28 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's balance sheet strengthens our fair value estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its long term debt to assets ratio, which lies in the top 1% compared with peers globally. The firm has a high level of long-term debt relative to its asset base, which can signal significant investment in the business or a pending merger. In either case, it may suggest future growth in cash flows. We believe this is a sign that shares could be undervalued.
Conversely, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, for example, falls in the top 50% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Inhibrx Biosciences discussion 0 comments